Shares of American Renal Associates Holdings Inc. (NYSE:ARA) hit a new 52-week low on Tuesday . The company traded as low as $25.51 and last traded at $26.02, with a volume of 253,080 shares changing hands. The stock had previously closed at $28.53.

A number of brokerages have recently weighed in on ARA. Barclays PLC began coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They issued an “overweight” rating and a $33.00 target price for the company. Leerink Swann began coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They issued an “outperform” rating and a $33.00 target price for the company. Goldman Sachs Group Inc. began coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They issued a “neutral” rating and a $30.00 target price for the company. Wells Fargo & Co. began coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They issued an “outperform” rating for the company. Finally, SunTrust Banks Inc. began coverage on American Renal Associates Holdings in a research note on Monday, May 16th. They issued a “buy” rating and a $34.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. American Renal Associates Holdings has a consensus rating of “Buy” and a consensus price target of $32.50.

The stock has a market capitalization of $566.58 million and a PE ratio of 12.99. The company has a 50 day moving average price of $0.00 and a 200 day moving average price of $0.00.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings data on Thursday, May 12th. The company reported $0.16 EPS for the quarter. The firm earned $172.10 million during the quarter, compared to analyst estimates of $149.30 million. Equities research analysts anticipate that American Renal Associates Holdings Inc. will post $0.88 EPS for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.